Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration.
Studies in various animal models have shown acebutolol to be a relatively cardioselective beta-adrenoceptor-blocking agent possessing both partial agonist and membrane-stabilizing activities. The latter property may not be significant at clinically used doses. Acebutolol has both antihypertensive and antiarrhythmic effects. As with beta blockers in general, the antihypertensive mechanism of acebutolol is not known. The antiarrhythmic activity of acebutolol may be related to beta blockade. Acebutolol is relatively hydrophilic and does not readily cross the blood-brain barrier, a fact that may be clinically significant in reducing the frequency and severity of central nervous system adverse effects. The pharmacologic profile of diacetolol, acebutolol's major metabolite, is similar to that of the parent compound in beta-blocking potency, cardioselectivity, and partial agonist activity. Diacetolol, however, does not possess membrane-stabilizing activity.
Abernethy
D R
DR
Arendt
R M
RM
Greenblatt
D J
DJ
D000070:Acebutolol / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001812:Blood-Brain Barrier / Q000187:drug effects; D002415:Cats; D002462:Cell Membrane / Q000187:drug effects; D004285:Dogs; D006168:Guinea Pigs; D006973:Hypertension / Q000188:drug therapy; D050356:Lipid Metabolism; D011433:Propranolol / Q000378:metabolism; D012995:Solubility; D013015:Sotalol / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; C025527:diacetolol; D000070:Acebutolol; D011433:Propranolol; D013015:Sotalol